Fluvoxamine drug
Pro Research Analysisby 
Searched over 200M research papers for "fluvoxamine drug"
Fluvoxamine: A Comprehensive Overview
Fluvoxamine for Anxiety Disorders in Children and Adolescents
Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), has shown significant efficacy in treating anxiety disorders in children and adolescents. In a study involving 128 children aged 6 to 17 years with social phobia, separation anxiety disorder, or generalized anxiety disorder, fluvoxamine significantly reduced anxiety symptoms compared to placebo. The Pediatric Anxiety Rating Scale scores decreased by an average of 9.7 points in the fluvoxamine group versus 3.1 points in the placebo group, with 76% of the fluvoxamine group showing improvement on the Clinical Global Impressions-Improvement scale compared to 29% in the placebo group . Additionally, fluvoxamine has been effective in reducing symptoms of obsessive-compulsive disorder (OCD) in pediatric patients, with significant improvements observed over short-term treatment periods Cheer2001Riddle2001.
Fluvoxamine in the Treatment of COVID-19
Recent studies have explored the potential of fluvoxamine in treating COVID-19. A meta-analysis of randomized clinical trials, including the STOP COVID 1 and 2 trials and the TOGETHER Trial, found that fluvoxamine reduced the risk of clinical deterioration or hospitalization by 31% compared to placebo. However, the reduction in hospitalization alone was not statistically significant . The TOGETHER Trial further supported these findings, showing that fluvoxamine reduced the need for extended emergency room observation or hospitalization among high-risk outpatients with early diagnosed COVID-19 .
Fluvoxamine as a Cytochrome P4501A2 Inhibitor
Fluvoxamine is a potent inhibitor of the cytochrome P4501A2 enzyme, which plays a crucial role in drug metabolism. This inhibition can lead to significant pharmacokinetic interactions with other drugs metabolized by CYP1A2, such as theophylline and imipramine. The inhibitor constant (Ki) of fluvoxamine ranges from 0.12 to 0.24 microM, making it a stronger inhibitor compared to other SSRIs .
Fluvoxamine for Binge-Eating Disorder
Fluvoxamine has also been investigated for its efficacy in treating binge-eating disorder. In a multicenter, placebo-controlled, double-blind trial involving 85 outpatients, fluvoxamine significantly reduced the frequency of binge-eating episodes and improved Clinical Global Impression (CGI) scale ratings compared to placebo. The study also noted improvements in body mass index and secondary measures, although a higher proportion of patients in the fluvoxamine group discontinued treatment due to adverse events .
Fluvoxamine for Social Phobia
In a 12-week, double-blind, placebo-controlled trial involving 92 patients with social phobia, fluvoxamine demonstrated significant efficacy. Patients treated with fluvoxamine showed greater improvements on the Clinical Global Impression of Improvement scale and specialized social phobia rating scales compared to those receiving placebo. Fluvoxamine also led to significant reductions in psychosocial disability measures .
Fluvoxamine and Clozapine-Related Metabolic Disturbances
Fluvoxamine has been shown to mitigate clozapine-related weight gain and metabolic disturbances. In a study involving 68 treatment-resistant schizophrenia patients, those receiving fluvoxamine in combination with low-dose clozapine had significantly lower increases in body weight, BMI, and serum glucose and triglyceride levels compared to those receiving clozapine monotherapy. This effect is attributed to fluvoxamine's ability to inhibit clozapine metabolism, thereby reducing the levels of its toxic metabolite, norclozapine .
Conclusion
Fluvoxamine is a versatile SSRI with proven efficacy in treating various conditions, including anxiety disorders in children and adolescents, binge-eating disorder, social phobia, and potentially COVID-19. Its role as a potent CYP1A2 inhibitor also highlights its importance in drug-drug interactions. While generally well-tolerated, careful monitoring is recommended, especially when used in combination with other medications. Further research is warranted to fully establish its long-term efficacy and safety across different patient populations.
Sources and full results
Most relevant research papers on this topic